Global NK Cell Therapy Market Insights, Forecast to 2025
Table of Contents
1 Study Coverage
- 1.1 NK Cell Therapy Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global NK Cell Therapy Market Size Growth Rate by Product
- 1.4.2 Mogamulizumab
- 1.4.3 Lorvotuzumab Mertansine
- 1.4.4 Others
- 1.5 Market by End User
- 1.5.1 Global NK Cell Therapy Market Size Growth Rate by End User
- 1.5.2 Cancer
- 1.5.3 Cardiovascular Diseases
- 1.5.4 Others
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global NK Cell Therapy Market Size
- 2.1.1 Global NK Cell Therapy Revenue 2014-2025
- 2.1.2 Global NK Cell Therapy Sales 2014-2025
- 2.2 NK Cell Therapy Growth Rate by Regions
- 2.2.1 Global NK Cell Therapy Sales by Regions
- 2.2.2 Global NK Cell Therapy Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 NK Cell Therapy Sales by Manufacturers
- 3.1.1 NK Cell Therapy Sales by Manufacturers
- 3.1.2 NK Cell Therapy Sales Market Share by Manufacturers
- 3.1.3 Global NK Cell Therapy Market Concentration Ratio (CR5 and HHI)
- 3.2 NK Cell Therapy Revenue by Manufacturers
- 3.2.1 NK Cell Therapy Revenue by Manufacturers (2014-2019)
- 3.2.2 NK Cell Therapy Revenue Share by Manufacturers (2014-2019)
- 3.3 NK Cell Therapy Price by Manufacturers
- 3.4 NK Cell Therapy Manufacturing Base Distribution, Product Types
- 3.4.1 NK Cell Therapy Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers NK Cell Therapy Product Type
- 3.4.3 Date of International Manufacturers Enter into NK Cell Therapy Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global NK Cell Therapy Sales by Product
- 4.2 Global NK Cell Therapy Revenue by Product
- 4.3 NK Cell Therapy Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global NK Cell Therapy Breakdown Data by End User
6 North America
- 6.1 North America NK Cell Therapy by Countries
- 6.1.1 North America NK Cell Therapy Sales by Countries
- 6.1.2 North America NK Cell Therapy Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America NK Cell Therapy by Product
- 6.3 North America NK Cell Therapy by End User
7 Europe
- 7.1 Europe NK Cell Therapy by Countries
- 7.1.1 Europe NK Cell Therapy Sales by Countries
- 7.1.2 Europe NK Cell Therapy Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe NK Cell Therapy by Product
- 7.3 Europe NK Cell Therapy by End User
8 Asia Pacific
- 8.1 Asia Pacific NK Cell Therapy by Countries
- 8.1.1 Asia Pacific NK Cell Therapy Sales by Countries
- 8.1.2 Asia Pacific NK Cell Therapy Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific NK Cell Therapy by Product
- 8.3 Asia Pacific NK Cell Therapy by End User
9 Central & South America
- 9.1 Central & South America NK Cell Therapy by Countries
- 9.1.1 Central & South America NK Cell Therapy Sales by Countries
- 9.1.2 Central & South America NK Cell Therapy Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America NK Cell Therapy by Product
- 9.3 Central & South America NK Cell Therapy by End User
10 Middle East and Africa
- 10.1 Middle East and Africa NK Cell Therapy by Countries
- 10.1.1 Middle East and Africa NK Cell Therapy Sales by Countries
- 10.1.2 Middle East and Africa NK Cell Therapy Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa NK Cell Therapy by Product
- 10.3 Middle East and Africa NK Cell Therapy by End User
11 Company Profiles
- 11.1 Chipscreen Biosciences (China)
- 11.1.1 Chipscreen Biosciences (China) Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Chipscreen Biosciences (China) NK Cell Therapy Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Chipscreen Biosciences (China) NK Cell Therapy Products Offered
- 11.1.5 Chipscreen Biosciences (China) Recent Development
- 11.2 Affimed NV (Netherlands)
- 11.2.1 Affimed NV (Netherlands) Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Affimed NV (Netherlands) NK Cell Therapy Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Affimed NV (Netherlands) NK Cell Therapy Products Offered
- 11.2.5 Affimed NV (Netherlands) Recent Development
- 11.3 Altor BioScience Corporation (USA)
- 11.3.1 Altor BioScience Corporation (USA) Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Altor BioScience Corporation (USA) NK Cell Therapy Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Altor BioScience Corporation (USA) NK Cell Therapy Products Offered
- 11.3.5 Altor BioScience Corporation (USA) Recent Development
- 11.4 Innate Pharma SA (France)
- 11.4.1 Innate Pharma SA (France) Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Innate Pharma SA (France) NK Cell Therapy Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Innate Pharma SA (France) NK Cell Therapy Products Offered
- 11.4.5 Innate Pharma SA (France) Recent Development
- 11.5 Takeda Pharmaceutical (Japan)
- 11.5.1 Takeda Pharmaceutical (Japan) Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Takeda Pharmaceutical (Japan) NK Cell Therapy Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Takeda Pharmaceutical (Japan) NK Cell Therapy Products Offered
- 11.5.5 Takeda Pharmaceutical (Japan) Recent Development
- 11.6 Sorrento Therapeutics Inc. (USA)
- 11.6.1 Sorrento Therapeutics Inc. (USA) Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Sorrento Therapeutics Inc. (USA) NK Cell Therapy Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Sorrento Therapeutics Inc. (USA) NK Cell Therapy Products Offered
- 11.6.5 Sorrento Therapeutics Inc. (USA) Recent Development
- 11.7 NantKwest Inc. (USA)
- 11.7.1 NantKwest Inc. (USA) Company Details
- 11.7.2 Company Business Overview
- 11.7.3 NantKwest Inc. (USA) NK Cell Therapy Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 NantKwest Inc. (USA) NK Cell Therapy Products Offered
- 11.7.5 NantKwest Inc. (USA) Recent Development
- 11.8 Bristol-Myers Squibb (USA)
- 11.8.1 Bristol-Myers Squibb (USA) Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Bristol-Myers Squibb (USA) NK Cell Therapy Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Bristol-Myers Squibb (USA) NK Cell Therapy Products Offered
- 11.8.5 Bristol-Myers Squibb (USA) Recent Development
- 11.9 NKT Therapeutics (USA)
- 11.9.1 NKT Therapeutics (USA) Company Details
- 11.9.2 Company Business Overview
- 11.9.3 NKT Therapeutics (USA) NK Cell Therapy Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 NKT Therapeutics (USA) NK Cell Therapy Products Offered
- 11.9.5 NKT Therapeutics (USA) Recent Development
12 Future Forecast
- 12.1 NK Cell Therapy Market Forecast by Regions
- 12.1.1 Global NK Cell Therapy Sales Forecast by Regions 2019-2025
- 12.1.2 Global NK Cell Therapy Revenue Forecast by Regions 2019-2025
- 12.2 NK Cell Therapy Market Forecast by Product
- 12.2.1 Global NK Cell Therapy Sales Forecast by Product 2019-2025
- 12.2.2 Global NK Cell Therapy Revenue Forecast by Product 2019-2025
- 12.3 NK Cell Therapy Market Forecast by End User
- 12.4 North America NK Cell Therapy Forecast
- 12.5 Europe NK Cell Therapy Forecast
- 12.6 Asia Pacific NK Cell Therapy Forecast
- 12.7 Central & South America NK Cell Therapy Forecast
- 12.8 Middle East and Africa NK Cell Therapy Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 NK Cell Therapy Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
The global NK Cell Therapy market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the NK Cell Therapy market based on company, product type, end user and key regions.
This report studies the global market size of NK Cell Therapy in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of NK Cell Therapy in these regions.
This research report categorizes the global NK Cell Therapy market by top players/brands, region, type and end user. This report also studies the global NK Cell Therapy market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Chipscreen Biosciences (China)
Affimed NV (Netherlands)
Altor BioScience Corporation (USA)
Innate Pharma SA (France)
Takeda Pharmaceutical (Japan)
Sorrento Therapeutics Inc. (USA)
NantKwest Inc. (USA)
Bristol-Myers Squibb (USA)
NKT Therapeutics (USA)
Market size by Product
Mogamulizumab
Lorvotuzumab Mertansine
Others
Market size by End User
Cancer
Cardiovascular Diseases
Others
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global NK Cell Therapy market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of NK Cell Therapy market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global NK Cell Therapy companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of NK Cell Therapy submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of NK Cell Therapy are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of NK Cell Therapy market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.